Urge Your Senators and Representatives to Support the Cancer Drug Parity Act
Legislation has been reintroduced in Congress that would ensure that patients enrolled in certain federally regulated health plans have access and insurance coverage for all anti-cancer regimens. The Cancer Drug Parity Act (S. 2039/H.R. 6301) would require any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered and self-injectable anticancer medications at a cost no less favorable than the cost of IV, port administered, or injected anticancer medications.
It's important for your elected officials to cosponsor this bill in order for it to be considered by the full Senate. Please take a moment to send an email to your Senators and Representative by filling out the form below. You are encouraged to personalize the letters as much as possible by providing examples of how the cost of oral or self-administered chemotherapy drugs has impacted you or your patients.
If you have any questions, please contact ASH Senior Manager, Legislative Advocacy, Tracy Roades at [email protected].
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission